Palisade Bio, Inc. (PALI)

NASDAQ: PALI · Real-Time Price · USD

0.6698

-0.0110 (-1.62%)

At close: Apr 1, 2025, 4:00 PM

0.6808

+0.0110 (1.64%)

After-hours: Apr 1, 2025, 4:55 PM EDT

Palisade Bio Employees

Palisade Bio had 9 employees as of December 31, 2023. The number of employees decreased by 3 or -25.00% compared to the previous year.

Employees

9

Change (1Y)

-3

Growth (1Y)

-25.00%

Revenue / Employee

n/a

Profits / Employee

-$1,604,222

Market Cap

2.94M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	9	-3	-25.00%
Dec 31, 2022	12	-1	-7.69%
Dec 31, 2021	13	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

PALI News

18 days ago - Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
20 days ago - Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewsWire
4 weeks ago - Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
5 weeks ago - Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
5 weeks ago - Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
7 weeks ago - Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
2 months ago - Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - GlobeNewsWire
3 months ago - Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire